Selecta Biosciences - SELB Stock Forecast, Price & News

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Analyst Ratings Changes

SELB has been the topic of several research reports. TheStreet raised Selecta Biosciences from a "d" rating to a "c-" rating in a research report on Wednesday, May 25th. StockNews.com raised Selecta Biosciences from a "hold" rating to a "buy" rating in a research report on Monday. Needham & Company LLC decreased their price target on Selecta Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, June 14th. SVB Leerink began coverage on shares of Selecta Biosciences in a research note on Monday, June 6th. They set an "outperform" rating and a $7.00 price objective on the stock. Finally, HC Wainwright decreased their target price on shares of Selecta Biosciences from $6.00 to $4.00 and set a "buy" rating for the company in a research note on Tuesday, June 21st. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Selecta Biosciences presently has a consensus rating of "Buy" and an average price target of $5.33.

Selecta Biosciences Stock Performance

NASDAQ:SELB traded down $0.02 during trading hours on Wednesday, reaching $2.42. 61,700 shares of the stock were exchanged, compared to its average volume of 2,070,679. The stock has a market capitalization of $369.56 million, a P/E ratio of 244.00 and a beta of 1.04. The firm has a 50 day simple moving average of $1.62 and a 200-day simple moving average of $1.44. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 0.25. Selecta Biosciences has a 52 week low of $0.65 and a 52 week high of $4.70.

Selecta Biosciences (NASDAQ:SELB - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.09. Selecta Biosciences had a net margin of 24.85% and a return on equity of 11.30%. During the same period in the prior year, the firm earned ($0.04) earnings per share. As a group, sell-side analysts forecast that Selecta Biosciences will post 0.18 earnings per share for the current fiscal year.

Insider Activity at Selecta Biosciences

In other Selecta Biosciences news, Director Carrie Smith Cox bought 130,000 shares of the business's stock in a transaction on Monday, June 13th. The shares were purchased at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the acquisition, the director now directly owns 212,881 shares of the company's stock, valued at approximately $244,813.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 30.50% of the company's stock.